Thetis Pharmaceuticals Announces U.S. Patent for TP-317 for Treatment of Colon Cancer (3/12/2024)

Expands Thetis composition of matter patent portfolio to treatment of solid tumor cancers.

ESSEX, CT – (March 12, 2024) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing an oral, small molecule Resolvin E1-based drug to treat cancer and chronic inflammatory diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has granted US. Pat # 11,925,688 providing a method of use claim for TP-317 (Resolvin E1 magnesium di-lysinate) for treatment of colon cancer. 

“TP-317 is a novel small molecule that represents a highly differentiated approach to regulating immune homeostasis with broad therapeutic potential in cancer and chronic inflammatory diseases,” said Gary Mathias, co-founder and CEO of Thetis. “In addition to composition of matter claims already issued in all major markets, Thetis now has an issued patent with a method of use claim supporting use of TP-317 for treatment of colon cancer, which is the second leading cause of cancer death in the U.S.”

About TP-317
Overview: TP-317 is a patented small molecule drug that delivers Resolvin E1, an endogenous lipid mediator that activates BLT1 to regulate immune homeostasis. Unlike anti-inflammatory drugs and anti-cancer agents that are immuno-suppressive, TP-317 activates innate and adaptive immune pathways to treat disease without compromising host-protective immunity.

Cancer Program: TP-317 is being developed in cancer as an adjunct to standard of care therapy in refractory metastatic melanoma, advanced non-small-cell lung cancer (NSCLC), and pancreatic cancer. Preclinical studies with oral TP-317 in tumor models of these cancers have shown potent single-agent activity, and enhanced efficacy when combined with immune checkpoint inhibitors or chemotherapy.

IBD Program: TP-317 is being developed in IBD as first-line, oral therapy for mild-to-moderate Crohn’s disease and as second-line, oral therapy for mild-to-moderate ulcerative colitis in patients who are not well controlled on 5-ASA or corticosteroids. TP-317 also has potential to treat moderate-to-severe IBD as adjunct therapy to standard-of-care biologics or oral immunomodulators. The anticipated high safety premium for TP-317 further supports early intervention in IBD and other immune disorders.

About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and chronic inflammatory diseases. Thetis’ proprietary HEALER™ technology enables the pharmaceutical development of Resolvins, overcoming the stability, manufacturing, and formulation hurdles that have limited their commercial development. Thetis is supported by venture capital investors, NIH, and leading private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.

Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration. 

Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) and follow Thetis on Twitter (@thetispharma) or email us at info@thetispharma.com